These data provide further support for the utility of LCN2 as a diagnostic biomarker of depression that can be assessed in combination with a range of other inflammatory markers, growth factors, and metabolic or endocrine changes when assessing the incidence of depressive symptoms. This evidence concerns the gene LCN2 and depressive symptom measurement.